Thanks to all above responding to the question; I agree that it indicates that the drug is not an approved Orphan drug in terms of marketing, but that the Orphan drug designation is granted. As an aside I wonder if there is any dispensation for continuing the release of the drug to those that were on it during the trial? Seems only fair, but fair isn't necessarily a prime concern in these matters, but given the safety profile...well...it seems fair.
Ajostu, if the FDA posted to their site that the designation was granted on 11/02/2015 as indicated, I would have thought that the Neuren team would have been advised on Thursday or Friday last week our time, enough time for a release to market about Orphan status. Which had me wondering about BTD being known and combined into a single release - pure speculation of course. But who knows - people could be in transit, there may be protocols that control communication to certain timelines and response cues.
Very interested to see a release on Monday, would almost have to arrive pre-open you'd think...
Thanks again to all who responded...have a great Sunday.
- Forums
- ASX - By Stock
- NEU
- FDA Grants Orphan Drug Designation
FDA Grants Orphan Drug Designation, page-19
-
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B |
Open | High | Low | Value | Volume |
$14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $13.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.07 | 6644 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 13.990 |
1 | 300 | 13.970 |
1 | 1432 | 13.950 |
2 | 1230 | 13.900 |
1 | 720 | 13.890 |
Price($) | Vol. | No. |
---|---|---|
14.420 | 175 | 1 |
14.500 | 2985 | 2 |
14.800 | 2850 | 2 |
14.860 | 500 | 1 |
14.960 | 445 | 1 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
NEU (ASX) Chart |